Silverarc Capital Management’s Astria Therapeutics ATXS Stock Holding History

Silverarc Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-93,823	Closed	-$1.25M	–	86
2023 Q1	$1.25M	Buy	93,823 +12,619	+16%	+$171K	0.52%	56
2022 Q4	$1.21M	Buy	+81,204	New	+$837K	0.35%	64
2021 Q3	–	Sell	-31,463	Closed	-$398	–	88
2021 Q2	$398	Buy	+31,463	New	+$409K	0.18%	85

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Silverarc Capital Management's ATXS Position: Q2 2023 in Review

Silverarc Capital Management sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 93,823 shares — an estimated $1.25M sold.

Silverarc Capital Management first reported a position in ATXS in Q2 2021 and held it in 3 quarters. The position peaked at $1.25M in Q1 2023. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

Silverarc Capital Management reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
Silverarc Capital Management sold 93,823 Astria Therapeutics shares in Q2 2023, an estimated $1.25M.
Silverarc Capital Management first reported a position in Astria Therapeutics in Q2 2021 and held it in 3 quarters.
Silverarc Capital Management's Astria Therapeutics position peaked at $1.25M in Q1 2023.
76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.